Lilianty J, Nur Patria Y, Stanley E, Elefanty A, Bateman J, Lamande S. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing. Stem Cell Res. 2020;45:101843 pubmed publisher

Nur Patria Y, Lilianty J, Elefanty A, Stanley E, Labonne T, Bateman J, et al. Generation of a SOX9-tdTomato reporter human iPSC line, MCRIi001-A-2, using CRISPR/Cas9 editing. Stem Cell Res. 2019;42:101689 pubmed publisher

Howden S, Hosseini Far H, Motazedian A, Elefanty A, Stanley E, Lamande S, et al. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line. Stem Cell Res. 2019;38:101453 pubmed publisher

Hosseini Far H, Patria Y, Motazedian A, Elefanty A, Stanley E, Lamande S, et al. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing. Stem Cell Res. 2019;37:101449 pubmed publisher

Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1. J Immunol. 2019;: pubmed publisher

Schutz C, Inselmann S, Saussele S, Dietz C, Mu Ller M, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829-836 pubmed publisher